共 50 条
- [41] A phase I/II study of docetaxel/epirubicin/bevacizumab (DEB) as first-line therapy for metastatic, HER2-negative breast cancer (MBC).JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Mavroudis, D.Boukovinas, I.Christophyllakis, C.Xenidis, N.Papakotoulas, P.Malamos, N. A.Kakolyris, S.Polyzos, A.Georgoulias, V.
- [42] Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancerBREAST CANCER RESEARCH AND TREATMENT, 2011, 125 (01) : 137 - 143Isaacs, ClaudineHerbolsheimer, PiaLiu, Minetta C.Wilkinson, MaryOttaviano, YvonneChung, Gina G.Warren, RobertEng-Wong, JenniferCohen, PhilipSmith, Karen L.Creswell, KarenNovielli, AntonellaSlack, Rebecca
- [43] A single arm phase II study of palbociclib in combination with tamoxifen as first line therapy for metastatic hormone receptor positive breast cancerCANCER RESEARCH, 2018, 78 (04)Danciu, Oana C.Hoskins, KentTamkus, DeimanteTruica, CristinaBlaes, AnneGreen, LaurenLiu, LiToppmeyer, DeborahWisinski, Kari
- [44] A phase II study of pemetrexed plus carboplatin as first-line therapy of patients with locally advanced (LA) or metastatic breast cancer (MBC): Preliminary results.JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 51S - 51SGarin, AManikhas, ABiakhov, MChezhin, MIvanchenko, TKrejcy, KKaraseva, VTjuyandin, S
- [45] Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancerEUROPEAN JOURNAL OF CANCER, 2021, 154 : 11 - 20Yuan, YuanLee, Jin SunYost, Susan E.Frankel, Paul H.Ruel, ChristopherEgelston, Colt A.Guo, WeihuaPadam, SimranTang, AileenMartinez, NormaSchmolze, DanielPresant, CaryEbrahimi, BehnamYeon, ChristinaSedrak, MinaPatel, NikiPortnow, JanaLee, PeterMortimer, Joanne
- [46] Trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: Phase II resultsJOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Gennatas, C. G.Michalaki, V.Gennatas, S.
- [47] First-line treatment of hormone receptor positive metastatic breast cancer (MBC) in everyday practice: Results from the Austrian AGMT_MBC-RegistryCANCER RESEARCH, 2021, 81 (04)Rinnerthaler, GabrielGampenrieder, Simon P.Tinchon, ChristophPetzer, Andreas LeoSuppan, ChristophHeibl, SonjaVoskova, DanielaZabernigg, August F.Egle, DanielSandholzer, MargitSinger, Christian F.Roitner, FlorianAndel, JohannesHubalek, MichaelKnauer, MichaelGreil, Richard
- [48] Treatment of HER2-positive (HER2+) hormone-receptor positive (HR plus ) metastatic breast cancer (mBC) with the novel combination of zanidatamab, palbociclib, and fulvestrantCANCER RESEARCH, 2023, 83 (05)Escriva-De-Romani, SantiagoAlba, EmilioRodriguez-Lescure, AlvaroHurvitz, SaraCejalvo, Juan MiguelGion, MariaFerrario, CristianoBorrego, Manuel RuizPezo, Rossanna C.Hamilton, ErikaWebster, MarcPluard, TimothyBeeram, MuralidharRodriguez, Begona JimenezLinden, HannahSaura, CristinaOmidpanah, AdamHarvey, PhoebeSavard, Marie-France
- [49] AKT1 alterations following exposure to endocrine-based therapy in patients with hormone-receptor positive (HR plus ) metastatic breast cancer (MBC): Clinical and functional implicationsCANCER RESEARCH, 2020, 80 (04)Wander, SethMao, PingpingLloyd, MaxwellKowalski, KaileyJohnson, Gabriela N.Malvarosa, GiulianaMoy, BeverlyEllisen, Leif W.Iafrate, JohnWagle, NikhilBardia, Aditya
- [50] Liposome-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: A phase II studyANNALS OF ONCOLOGY, 2006, 17 : VII145 - VII145Latiano, T. P.D'Addetta, C.Tozzi, L.Cilenti, G.Piano, A.Valori, V. M.Bisceglia, M.Maiello, E.